| Dr Raghavendra Rao Siragavarapu, MD | |
|
1401 Marlton Pike E Ste 27, Cherry Hill, NJ 08034-2207 | |
| (856) 872-7055 | |
| Not Available |
| Full Name | Dr Raghavendra Rao Siragavarapu |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 25 Years |
| Location | 1401 Marlton Pike E Ste 27, Cherry Hill, New Jersey |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154582377 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Delaware County Professional Services, Inc | 2668436692 | 99 |
| Eastern Pennsylvania Physician Alliance, Llc | 8325478662 | 92 |
News Archive
Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins. In fact, the possibilities of identifying more than 10,000 novel target antigens in the human genome may accelerate the discovery of new drugs and therapeutic molecules.
People with severe mental illness are more than twice as likely to have Type 2 diabetes, with even higher risks among patients who are African American or Hispanic, according to a new study led by UCSF.
Scanning a premature infant's brain shortly after birth to map the location and volume of lesions, small areas of injury in the brain's white matter, may help doctors better predict whether the baby will have disabilities later, according to a new study published in the January 18, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.
KineMed, Inc. today announced a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
› Verified 3 days ago
| Entity Name | Uhs Of Pennsylvania, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225128192 PECOS PAC ID: 3971407438 Enrollment ID: O20031208000129 |
News Archive
Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins. In fact, the possibilities of identifying more than 10,000 novel target antigens in the human genome may accelerate the discovery of new drugs and therapeutic molecules.
People with severe mental illness are more than twice as likely to have Type 2 diabetes, with even higher risks among patients who are African American or Hispanic, according to a new study led by UCSF.
Scanning a premature infant's brain shortly after birth to map the location and volume of lesions, small areas of injury in the brain's white matter, may help doctors better predict whether the baby will have disabilities later, according to a new study published in the January 18, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.
KineMed, Inc. today announced a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
› Verified 3 days ago
| Entity Name | Delaware County Professional Services, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952485864 PECOS PAC ID: 2668436692 Enrollment ID: O20041118000546 |
News Archive
Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins. In fact, the possibilities of identifying more than 10,000 novel target antigens in the human genome may accelerate the discovery of new drugs and therapeutic molecules.
People with severe mental illness are more than twice as likely to have Type 2 diabetes, with even higher risks among patients who are African American or Hispanic, according to a new study led by UCSF.
Scanning a premature infant's brain shortly after birth to map the location and volume of lesions, small areas of injury in the brain's white matter, may help doctors better predict whether the baby will have disabilities later, according to a new study published in the January 18, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.
KineMed, Inc. today announced a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
› Verified 3 days ago
| Entity Name | Friends Behavioral Health System, Lp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023099405 PECOS PAC ID: 6002858891 Enrollment ID: O20060822000480 |
News Archive
Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins. In fact, the possibilities of identifying more than 10,000 novel target antigens in the human genome may accelerate the discovery of new drugs and therapeutic molecules.
People with severe mental illness are more than twice as likely to have Type 2 diabetes, with even higher risks among patients who are African American or Hispanic, according to a new study led by UCSF.
Scanning a premature infant's brain shortly after birth to map the location and volume of lesions, small areas of injury in the brain's white matter, may help doctors better predict whether the baby will have disabilities later, according to a new study published in the January 18, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.
KineMed, Inc. today announced a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
› Verified 3 days ago
| Entity Name | Belmont Behavioral Hospital Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629468137 PECOS PAC ID: 1153636691 Enrollment ID: O20151208000473 |
News Archive
Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins. In fact, the possibilities of identifying more than 10,000 novel target antigens in the human genome may accelerate the discovery of new drugs and therapeutic molecules.
People with severe mental illness are more than twice as likely to have Type 2 diabetes, with even higher risks among patients who are African American or Hispanic, according to a new study led by UCSF.
Scanning a premature infant's brain shortly after birth to map the location and volume of lesions, small areas of injury in the brain's white matter, may help doctors better predict whether the baby will have disabilities later, according to a new study published in the January 18, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.
KineMed, Inc. today announced a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
› Verified 3 days ago
| Entity Name | Eastern Pennsylvania Physician Alliance, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902440621 PECOS PAC ID: 8325478662 Enrollment ID: O20200428001935 |
News Archive
Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins. In fact, the possibilities of identifying more than 10,000 novel target antigens in the human genome may accelerate the discovery of new drugs and therapeutic molecules.
People with severe mental illness are more than twice as likely to have Type 2 diabetes, with even higher risks among patients who are African American or Hispanic, according to a new study led by UCSF.
Scanning a premature infant's brain shortly after birth to map the location and volume of lesions, small areas of injury in the brain's white matter, may help doctors better predict whether the baby will have disabilities later, according to a new study published in the January 18, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.
KineMed, Inc. today announced a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Raghavendra Rao Siragavarapu, MD 1401 Marlton Pike E Ste 27, Cherry Hill, NJ 08034-2207 Ph: (856) 448-4989 | Dr Raghavendra Rao Siragavarapu, MD 1401 Marlton Pike E Ste 27, Cherry Hill, NJ 08034-2207 Ph: (856) 872-7055 |
News Archive
Functional genomics and proteomics have been quite successful in identifying functions of potential therapeutic targets such as encoded proteins. In fact, the possibilities of identifying more than 10,000 novel target antigens in the human genome may accelerate the discovery of new drugs and therapeutic molecules.
People with severe mental illness are more than twice as likely to have Type 2 diabetes, with even higher risks among patients who are African American or Hispanic, according to a new study led by UCSF.
Scanning a premature infant's brain shortly after birth to map the location and volume of lesions, small areas of injury in the brain's white matter, may help doctors better predict whether the baby will have disabilities later, according to a new study published in the January 18, 2017, online issue of Neurology®, the medical journal of the American Academy of Neurology.
KineMed, Inc. today announced a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.
› Verified 3 days ago
Thomas O'reilly, Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2250 Chapel Ave W, Suite 100, Cherry Hill, NJ 08002 Phone: 856-482-9000 Fax: 856-482-1159 | |
Dr. Badal D Rana, D.O Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2250 Chapel Ave W, Cherry Hill, NJ 08002 Phone: 856-482-9000 | |
Dr. Harry Madison, D.O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2250 Chapel Ave W, Suite 100, Cherry Hill, NJ 08002 Phone: 856-482-9000 Fax: 856-482-1159 | |
Allen C Zechowy, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 63 Kresson Road, Suite 101, Cherry Hill, NJ 08034 Phone: 856-795-2000 Fax: 856-795-3625 | |
Dr. Perry Howard Zand, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2201 Chapel Avenue West, Suite 104, Cherry Hill, NJ 08002 Phone: 856-662-1122 Fax: 856-429-4212 | |
Hatice Burakgazi Yilmaz, MD, MS Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2250 Chapel Ave W, Suite 100, Cherry Hill, NJ 08002 Phone: 856-482-9000 Fax: 856-482-1159 | |
Gino Grosso, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1930 Marlton Pike E, Suite G-38, Cherry Hill, NJ 08003 Phone: 856-751-7280 Fax: 856-751-7209 |